---
title: "Global and China 2-chloronicotinicacid Market Insights, Forecast to 2025-2032"
datePublished: Sat Oct 11 2025 09:42:23 GMT+0000 (Coordinated Universal Time)
cuid: cmgm36vw0000002i37lg41otn
slug: global-and-china-2-chloronicotinicacid-market-insights-forecast-to-2025-2032

---

# Global and China 2-chloronicotinicacid Market Insights, Forecast to 2025-2032

<p><strong>MARKET INSIGHTS</strong></p><p>
</p><p>Global 2-chloronicotinic acid market size was valued at <strong>USD 128.5 million in 2024.</strong> The market is projected to grow from <strong>USD 136.2 million in 2025 to USD 198.7 million by 2032, exhibiting a CAGR of 5.4%</strong> during the forecast period.</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/116208/global-china-chloronicotinicacid-market-2027-174">
            https://www.24chemicalresearch.com/download-sample/116208/global-china-chloronicotinicacid-market-2027-174</a></b></div><br><p>
</p><p>2-chloronicotinic acid is an important chemical intermediate widely used in pharmaceutical and agrochemical applications. This chlorinated pyridine derivative serves as a key building block in synthesizing various active pharmaceutical ingredients (APIs) and crop protection chemicals. The compound exists in two primary grades - pharmaceutical grade with purity ≥99% and industrial grade with purity ≥98% - each serving distinct application needs.</p><p>
</p><p>Market growth is primarily driven by expanding pharmaceutical production in emerging economies and increasing demand for novel pesticides. While China dominates global production capacity with manufacturers like Zhejiang Rongkai Technology and Jiangsu Zhongzheng Biochemical, multinational players such as Koei Chemical and Jubilant Life Sciences continue expanding their market presence through strategic partnerships and capacity expansions. The pharmaceutical industry segment accounted for over 60% of total demand in 2024, though pesticide applications are growing faster at an estimated 6.1% CAGR through 2032.</p><p>
</p><p><img alt="WebP Preview" src="data:image/webp;base64,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"></p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Expanding Pharmaceutical Applications to Fuel 2-Chloronicotinic Acid Demand</strong></p><p>
</p><p>Global pharmaceutical industry's growth is significantly boosting 2-chloronicotinic acid consumption, particularly in active pharmaceutical ingredient (API) manufacturing. With the pharmaceutical grade segment projected to grow at over 6% CAGR through 2032, demand for high-purity intermediates like 2-chloronicotinic acid continues rising. This compound serves as a crucial building block for synthesizing various drugs, including cardiovascular medications and neurological treatments. Recent regulatory approvals for novel drug formulations in major markets have further accelerated its adoption, particularly in China where pharmaceutical production capacity increased by nearly 18% between 2020-2024.</p><p>
</p><p style="text-align:center"><strong>Agricultural Chemical Sector Growth Driving Industrial Usage</strong></p><p>
</p><p>2-chloronicotinic acid plays a vital role in synthesizing advanced agricultural chemicals, particularly neonicotinoid insecticides. Despite regulatory scrutiny on certain pesticide classes, the global agrochemical market expansion - projected to exceed <strong>USD300 billion by 2032 </strong>- sustains demand. China's dominant position in pesticide production, accounting for approximately 40% of global output, creates concentrated demand within the Asia-Pacific region. The compound's effectiveness in creating systemic pesticides that protect crops against sucking insects continues to drive its adoption, particularly in tropical agriculture regions facing increasing pest resistance challenges.</p><p>
</p><p>Recent developments in precision farming techniques and controlled-release formulations have opened new application avenues for 2-chloronicotinic acid derivatives.</p><p>
</p><p>Furthermore, strategic partnerships between agrochemical giants and specialty chemical producers are expected to enhance production capabilities and regional market penetration.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Stringent Environmental Regulations Limiting Market Expansion</strong></p><p>
</p><p>2-chloronicotinic acid market faces significant constraints from increasingly strict environmental regulations worldwide. Chlorinated compound manufacturing processes face particular scrutiny due to potential ecological impacts, with production facilities required to implement costly waste treatment systems. In Europe, REACH regulations have led to approval delays for several chlorinated intermediates, while China's evolving environmental policies have forced production capacity rationalizations. Compliance costs now represent approximately 12-15% of total production expenses for manufacturers, squeezing profit margins and discouraging new market entrants.</p><p>
</p><p><strong>Other Restraints</strong></p><p>
</p><p style="text-align:center"><strong>Price Volatility of Raw Materials</strong></p><p>
</p><p>Fluctuations in key feedstock prices, particularly pyridine derivatives, create pricing instability for 2-chloronicotinic acid. Supply chain disruptions following geopolitical events have caused raw material costs to vary by as much as 30% year-over-year, making long-term contract pricing challenging for manufacturers.</p><p>
</p><p style="text-align:center"><strong>Substitute Availability</strong></p><p>
</p><p>Emerging alternative chemistries in both pharmaceutical and pesticide formulations threaten to displace certain applications of 2-chloronicotinic acid. Novel synthesis routes using non-chlorinated intermediates are gaining traction among environmentally conscious formulators.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Technical Complexities in Production Processes</strong></p><p>
</p><p>Manufacturing high-purity 2-chloronicotinic acid requires precise control of chlorination reactions and purification steps, presenting significant technical hurdles. Achieving pharmaceutical-grade purity (typically &gt;99%) demands specialized equipment and rigorous quality control measures that many regional producers lack. The highly corrosive nature of intermediate compounds accelerates equipment wear, increasing maintenance costs by an estimated 20-25% compared to non-chlorinated chemical production lines.</p><p>
</p><p>Additionally, maintaining consistent product quality while scaling up production remains a persistent challenge, particularly when serving regulated pharmaceutical markets requiring batch-to-batch consistency documentation.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Growth in Generic Drug Production Creating New Demand Centers</strong></p><p>
</p><p>Impending patent cliff for several blockbuster drugs presents substantial opportunities for 2-chloronicotinic acid suppliers. With over <strong>USD200 billion</strong> worth of branded pharmaceuticals losing exclusivity by 2032, generic drug manufacturers are ramping up API production. This creates robust demand for cost-effective intermediates, particularly in emerging pharmaceutical hubs across Asia. India's generic drug industry, which supplies approximately 20% of global generic volume, represents a particularly promising growth market with domestic production of key intermediates expected to double by 2030.</p><p>
</p><p>Moreover, China's pharmaceutical industry upgrade initiatives are driving modernization of intermediate production facilities, presenting equipment and technology transfer opportunities for international chemical suppliers.</p><p>
</p><p style="text-align:center"><strong>Emerging Markets Offer Untapped Potential</strong></p><p>
</p><p>Latin America and Southeast Asia represent high-growth opportunities due to expanding local pharmaceutical and agrochemical production capabilities. Brazil's domestic pesticide market has grown at 8% CAGR since 2020, while Indonesia's pharmaceutical sector expansion creates new demand for imported intermediates. Local production constraints in these markets favor established 2-chloronicotinic acid suppliers who can ensure reliable quality and supply chain stability. Strategic partnerships with regional distributors are becoming increasingly important to capitalize on these developing opportunities.</p><p>
<strong>MARKET TRENDS</strong></p><p>
<strong>Pharmaceutical Industry Demand Driving Market Growth</strong></p><p>
</p><p>Global 2-chloronicotinic acid market is experiencing steady growth, primarily fueled by increasing demand from the <strong>pharmaceutical sector</strong>. As a key intermediate in synthesizing various active pharmaceutical ingredients (APIs), this specialty chemical plays a crucial role in producing numerous medications. The pharmaceutical grade segment currently accounts for approximately <strong>65%</strong> of total market volume, with expanding applications in antiviral and antibacterial drug formulations. China's robust API manufacturing ecosystem has positioned it as both a major consumer and producer, contributing nearly <strong>40%</strong> of global output in 2024. The market is projected to maintain a CAGR of <strong>5.2%</strong> through 2032 as new therapeutic applications continue to emerge.</p><p>
<strong>Other Trends</strong></p><p>
</p><p style="text-align:center"><strong>Agrochemical Applications Expansion</strong></p><p>
</p><p>While pharmaceutical applications dominate, the <strong>pesticide industry</strong> is emerging as a significant growth driver for 2-chloronicotinic acid. The compound serves as a critical building block for novel neonicotinoid insecticides, despite regulatory challenges surrounding certain derivatives. Manufacturers are investing in developing next-generation crop protection solutions with improved environmental profiles, creating demand for high-purity intermediates. The industrial grade segment, primarily serving agrochemical producers, is anticipated to grow at <strong>4.8%</strong> annually through the forecast period.</p><p>
<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Strategic Expansion and R&amp;D Investments Drive Market Competitiveness</strong></p><p>
</p><p>Global <strong>2-chloronicotinic acid market</strong> exhibits a semi-consolidated structure, with key players competing across pharmaceutical and agrochemical applications. <strong>Koei Chemical</strong> leads the market with its extensive production capabilities and strong foothold in Asia-Pacific, particularly in pharmaceutical-grade segments. The company's expansion into high-purity applications for active pharmaceutical ingredients (APIs) has reinforced its market position.</p><p>
</p><p>Meanwhile, <strong>Jubilant Life Sciences</strong> has emerged as another major contender, leveraging its vertically integrated manufacturing processes to maintain cost efficiency. The company holds <strong>15-18% market share in India's agrochemical sector</strong> as of 2024, with significant capacity expansions planned through 2027. Their focus on custom synthesis for multinational corporations provides a competitive edge in contract manufacturing.</p><p>
</p><p>Chinese manufacturers like <strong>Zhejiang Rongkai Technology</strong> and <strong>Jiangsu Zhongzheng Biochemical</strong> dominate regional markets through economies of scale, collectively accounting for <strong>over 30% of Asia-Pacific production capacity</strong>. These players are increasingly targeting export markets with competitively priced industrial-grade products, though quality standardization remains an ongoing challenge.</p><p>
<strong>List of Key Profiled</strong></p><p>
</p><p><strong>Koei Chemical Co., Ltd. (Japan)</strong></p><p>Jubilant Life Sciences Ltd. (India)</p><p>Zhejiang Rongkai Technology Co., Ltd. (China)</p><p>Jiangsu Zhongzheng Biochemical Co., Ltd. (China)</p><p>Xiangyang King Success Chemical Co., Ltd. (China)</p><p>Jiangsu Hankuo Biology Co., Ltd. (China)</p><p>Donghai Taiyi Fine Chemical Co., Ltd. (China)</p><p>
</p><p>Smaller regional players are adopting niche strategies, with companies like <strong>Xiangyang King Success Chemical</strong> specializing in pesticide intermediates. The market sees increasing M&amp;A activity as multinationals seek to establish production bases in China - a trend expected to accelerate through 2032 with the country's <strong>chemical output projected to grow at 5.8% CAGR</strong>.</p><p>
</p><p>Quality certifications and regulatory compliance are becoming key differentiators, particularly for EU and North American markets. While Chinese manufacturers dominate volume production, Japanese and Indian firms maintain premium positioning through superior process technologies and cleaner production methods.</p><p>
<strong>Segment Analysis:</strong></p><p>
<strong>By Type</strong></p><p>
</p><p><strong>Pharmaceutical Grade Dominates the Market Due to Increasing Usage in Drug Formulations</strong></p><p>
</p><p>Global and China 2-chloronicotinic acid market is segmented based on type into:</p><p>
</p><p>Industrial Grade</p><p>Pharmaceutical Grade</p><p>
<strong>By Application</strong></p><p>
</p><p><strong>Pharmaceutical Industry Leads the Market Owing to Growing Demand for Active Pharmaceutical Ingredients</strong></p><p>
</p><p>Market is segmented based on application into:</p><p>
</p><p>Pharmaceutical Industry</p><p>Pesticide Industry</p><p>
<strong>By Region</strong></p><p>
</p><p><strong>Asia-Pacific Holds Significant Market Share Fueled by Expanding Pharmaceutical Production in China and India</strong></p><p>
</p><p>Market is segmented by region into:</p><p>
</p><p>North America</p><p>Europe</p><p>Asia-Pacific</p><p>Latin America</p><p>Middle East &amp; Africa</p><p>
<strong>Report Scope</strong></p><p>
</p><p>This report presents a comprehensive analysis of the Global and China markets for 2-chloronicotinicacid, covering the period from 2024 to 2032. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed 2-chloronicotinicacid companies and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global 2-chloronicotinicacid Market?</strong></p><p>
</p><p><strong>-&gt;</strong> Global 2-chloronicotinic acid market size was valued at USD 128.5 million in 2024. The market is projected to grow from USD 136.2 million in 2025 to USD 198.7 million by 2032, exhibiting a CAGR of 5.4% during the forecast period.</p><p>
<strong>Which key companies operate in Global 2-chloronicotinicacid Market?</strong></p><p>
</p><p>-&gt; Key players include Koei Chemical, Jubilant Life Sciences, Zhejiang Rongkai Technology, Jiangsu Zhongzheng Biochemical, Xiangyang King Success Chemical, Jiangsu Hankuo Biology, and Donghai Taiyi Fine Chemical.</p><p>
<strong>What are the key growth drivers?</strong></p><p>
</p><p>-&gt; Key growth drivers include rising demand from pharmaceutical and pesticide industries, increasing R&amp;D investments, and expansion of agrochemical sectors in emerging economies.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p>-&gt; Asia-Pacific is the largest market, with China accounting for over 35% of global production capacity in 2024.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include development of high-purity pharmaceutical grade products, green synthesis methods, and increasing applications in novel drug formulations.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/116208/global-china-chloronicotinicacid-market-2027-174">
            https://www.24chemicalresearch.com/reports/116208/global-china-chloronicotinicacid-market-2027-174</a></b></div><br>
            <b>Table of Content:</b><p>1 Study Coverage<br />
    1.1 2-chloronicotinicacid Product Introduction<br />
    1.2 Market by Type<br />
        1.2.1 Global 2-chloronicotinicacid Market Size Growth Rate by Type<br />
        1.2.2 Industrial Grade<br />
        1.2.3 Pharmaceutical Grade<br />
    1.3 Market by Application<br />
        1.3.1 Global 2-chloronicotinicacid Market Size Growth Rate by Application<br />
        1.3.2 Pharmaceutical Industry<br />
        1.3.3 Pesticide Industry<br />
    1.4 Study Objectives<br />
    1.5 Years Considered<br />
<br />
2 Executive Summary<br />
    2.1 Global 2-chloronicotinicacid Market Size, Estimates and Forecasts<br />
        2.1.1 Global 2-chloronicotinicacid Revenue 2016-2027<br />
        2.1.2 Global 2-chloronicotinicacid Sales 2016-2027<br />
    2.2 Global 2-chloronicotinicacid, Market Size by Region: 2016 VS 2021 VS 2027<br />
    2.3 2-chloronicotinicacid Historical Market Size by Region (2016-2021)<br />
        2.3.1 Global 2-chloronicotinicacid Retrospective Market Scenario in Sales by Region: 2016-2021<br />
        2.3.2 Global 2-chloronicotinicacid Retrospective Market Scenario in Revenue by Region: 2016-2021<br />
    2.4 2-chloronicotinicacid Market Estimates and Projections by Region (2022-2027)<br />
        2.4.1 Global 2-chloronicotinicacid Sales Forecast by Region (2022-2027)<br />
        2.4.2 Global 2-chloronicotinicacid Revenue Forecast by Region (2022-2027)<br />
<br />
3 Global 2-chloronicotinicacid Competitor Landscape by Players<br />
    3.1 Global Top 2-chloronicotinicacid Manufacturers by Sales<br />
        3.1.1 Global 2-chloronicotinicacid Sales by M</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/116208/global-china-chloronicotinicacid-market-2027-174">
            https://www.24chemicalresearch.com/reports/116208/global-china-chloronicotinicacid-market-2027-174</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>